SEC Company Response from Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Oct 25, 2018

Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: Oct. 25, 2018 · CIK: 0001659617 · Accession: 0001144204-18-055246

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-227845

Date

October 24, 2018

Author

Jonathan Foster

Form

CORRESP

Company

Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)

Letter

Re: Moleculin Biotech, Inc.

October 25,

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Registration Statement on Form S-1

Registration No. 333-227845

Ladies and Gentlemen:

Reference is made to the letter request of Moleculin Biotech, Inc., a Delaware corporation (the “Company”), for acceleration of effectiveness of the above-captioned registration statement submitted to the U.S. Securities and Exchange Commission (the “Commission”) on October 24, 2018, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Acceleration Request”).

The Acceleration Request inadvertently included an incorrect date for acceleration. The undersigned hereby respectfully requests that the Commission withdraw the Acceleration Request and that it not declare the above-captioned registration statement effective until such time as the Company shall request pursuant to a new request.

Very truly yours,
Moleculin Biotech, Inc.

Show Raw Text

CORRESP
1
filename1.htm

October 25,
2018

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 Re: Moleculin Biotech, Inc.

Registration Statement on Form
S-1

Registration No. 333-227845

Ladies and Gentlemen:

Reference is made to
the letter request of Moleculin Biotech, Inc., a Delaware corporation (the “Company”), for acceleration of effectiveness
of the above-captioned registration statement submitted to the U.S. Securities and Exchange Commission (the “Commission”)
on October 24, 2018, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Acceleration Request”).

The Acceleration Request
inadvertently included an incorrect date for acceleration. The undersigned hereby respectfully requests that the Commission withdraw
the Acceleration Request and that it not declare the above-captioned registration statement effective until such time as the Company
shall request pursuant to a new request.

    Very truly yours,

    Moleculin Biotech, Inc.

    By:
    /s/ Jonathan Foster

    Name: Jonathan Foster

    Title: Chief Financial Officer

SecProbe.io